{
    "clinical_study": {
        "@rank": "29976", 
        "acronym": "HEPATOFLUO", 
        "arm_group": {
            "arm_group_label": "Fluobeam", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is a prospective, monocentric, non-randomized, phase I-II study. The goal is to assess\n      the faisability and the capabilities of fluorescence imaging in hepatic surgery, and\n      specially to help the surgeon while performing liver surgery.\n\n      This study will be performed on patient intended to undergo a liver cancer surgery.It will\n      contain three steps, assessing the following items:\n\n        -  Step 1: to assess the faisability of the use of the Fluobeam, in actual clinical\n           surgical conditions and validate the data obtained in the preclinical phase,\n\n        -  Step 2: to assess the ability of the combination of ICG and Fluobeam to mark hepatic\n           lesions,\n\n        -  Step 3: to assess the ability of the combination of ICG and Fluobeam to help in guiding\n           per-hepatectomy.\n\n           3 to 6 patients will be enrolled in the first step, 20 in the second step and 20 in the\n           third step.\n\n      Patients will be followed during 4 weeks after the surgery."
        }, 
        "brief_title": "Assessment of Indocyanine Green as a Near-Infrared Fluorescent Contrast Agent for Image-guided Liver Surgery", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Liver Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Liver Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patient\n\n          -  Affected of hepatic cancerous lesions whatever they are\n\n          -  Requiring a one or two steps hepatectomy by laparotomy\n\n          -  ECOG performance status (PS)\u2264 2\n\n          -  Mandatory affiliation to health security insurance\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  With a contraindication or hypersensitivity to ICG administration in medical history\n\n          -  Having already undergone a major hepatic surgery (more than three segments) or major\n             biliar surgery (context of major iterative hepatic surgery)\n\n          -  Unable to be followed during the duration of the study, for social, family,\n             geographical or psychological reasons\n\n          -  Pregnant or breast-feeding woman (urinary strip must be negative at the time of the\n             inclusion in the study for women in age to procreate)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "46", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01738217", 
            "org_study_id": "HEPATOFLUO", 
            "secondary_id": "ET12-066"
        }, 
        "intervention": {
            "arm_group_label": "Fluobeam", 
            "intervention_name": "Fluobeam", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Intra-operative imaging", 
            "NIR Fluorescence", 
            "Liver surgery", 
            "Tumoral margins"
        ], 
        "lastchanged_date": "January 30, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Lyon Cedex 08", 
                    "country": "France", 
                    "zip": "69373"
                }, 
                "name": "Centre L\u00e9on B\u00e9rard"
            }, 
            "investigator": [
                {
                    "last_name": "Patrice Peyrat, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Michel RIVOIRE, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Aur\u00e9lien DUPRE, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Evaluation, for Patients Requiring a Liver Cancer Surgery, of the Use of Fluorescence Imaging Device: Faisability and Efficiency of Lesional and/or Anatomical Marking", 
        "overall_contact": {
            "email": "ellen.blanc@lyon.unicancer.fr", 
            "last_name": "Ellen BLANC", 
            "phone": "+33 478 78 29 67"
        }, 
        "overall_official": {
            "affiliation": "Centre L\u00e9on B\u00e9rard, LYON, FRANCE.", 
            "last_name": "Patrice Peyrat", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The ability to detect fluorescence\nThe ability to investigate the mobilized parenchyma\nThe ability to use the medical device following requested asepsis procedures\nSurgeon satisfaction\nNurse satisfaction", 
                "measure": "First step: assess the feasibility and the acceptability of Fluobeam", 
                "safety_issue": "No", 
                "time_frame": "During surgery on day 0"
            }, 
            {
                "measure": "Second step: assess the rate of patients in whom, all of the lesions (superficial/deep) will be detected by means of the Fluobeam medical device in peroperative or in postoperative.", 
                "safety_issue": "No", 
                "time_frame": "During surgery on day 0"
            }, 
            {
                "measure": "Third step: assess the rate of patients in whom, among the 7 liver segments, the surgeon will be able to selectively target a predefined area.", 
                "safety_issue": "No", 
                "time_frame": "During surgery on day 0"
            }
        ], 
        "reference": [
            {
                "PMID": "19844652", 
                "citation": "Aoki T, Murakami M, Yasuda D, Shimizu Y, Kusano T, Matsuda K, Niiya T, Kato H, Murai N, Otsuka K, Kusano M, Kato T. Intraoperative fluorescent imaging using indocyanine green for liver mapping and cholangiography. J Hepatobiliary Pancreat Sci. 2010 Sep;17(5):590-4. Epub 2009 Oct 21."
            }, 
            {
                "PMID": "18543027", 
                "citation": "Aoki T, Yasuda D, Shimizu Y, Odaira M, Niiya T, Kusano T, Mitamura K, Hayashi K, Murai N, Koizumi T, Kato H, Enami Y, Miwa M, Kusano M. Image-guided liver mapping using fluorescence navigation system with indocyanine green for anatomical hepatic resection. World J Surg. 2008 Aug;32(8):1763-7."
            }, 
            {
                "PMID": "9809562", 
                "citation": "Billingsley KG, Jarnagin WR, Fong Y, Blumgart LH. Segment-oriented hepatic resection in the management of malignant neoplasms of the liver. J Am Coll Surg. 1998 Nov;187(5):471-81."
            }, 
            {
                "PMID": "19301311", 
                "citation": "Gotoh K, Yamada T, Ishikawa O, Takahashi H, Eguchi H, Yano M, Ohigashi H, Tomita Y, Miyamoto Y, Imaoka S. A novel image-guided surgery of hepatocellular carcinoma by indocyanine green fluorescence imaging navigation. J Surg Oncol. 2009 Jul 1;100(1):75-9."
            }, 
            {
                "PMID": "19326450", 
                "citation": "Ishizawa T, Fukushima N, Shibahara J, Masuda K, Tamura S, Aoki T, Hasegawa K, Beck Y, Fukayama M, Kokudo N. Real-time identification of liver cancers by using indocyanine green fluorescent imaging. Cancer. 2009 Jun 1;115(11):2491-504."
            }, 
            {
                "PMID": "22260827", 
                "citation": "Ishizuka M, Kubota K, Kita J, Shimoda M, Kato M, Sawada T. Intraoperative observation using a fluorescence imaging instrument during hepatic resection for liver metastasis from colorectal cancer. Hepatogastroenterology. 2012 Jan-Feb;59(113):90-2. doi: 10.5754/hge11223."
            }, 
            {
                "PMID": "11333094", 
                "citation": "Jarnagin WR, Bach AM, Winston CB, Hann LE, Heffernan N, Loumeau T, DeMatteo RP, Fong Y, Blumgart LH. What is the yield of intraoperative ultrasonography during partial hepatectomy for malignant disease? J Am Coll Surg. 2001 May;192(5):577-83."
            }, 
            {
                "PMID": "22200990", 
                "citation": "Morita Y, Sakaguchi T, Unno N, Shibasaki Y, Suzuki A, Fukumoto K, Inaba K, Baba S, Takehara Y, Suzuki S, Konno H. Detection of hepatocellular carcinomas with near-infrared fluorescence imaging using indocyanine green: its usefulness and limitation. Int J Clin Oncol. 2013 Apr;18(2):232-41. doi: 10.1007/s10147-011-0367-3. Epub 2011 Dec 27."
            }, 
            {
                "PMID": "15849507", 
                "citation": "Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, Curley SA, Loyer EM, Muratore A, Mentha G, Capussotti L, Vauthey JN. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005 May;241(5):715-22, discussion 722-4."
            }, 
            {
                "PMID": "14769718", 
                "citation": "Reuthebuch O, H\u00e4ussler A, Genoni M, Tavakoli R, Odavic D, Kadner A, Turina M. Novadaq SPY: intraoperative quality assessment in off-pump coronary artery bypass grafting. Chest. 2004 Feb;125(2):418-24."
            }, 
            {
                "PMID": "21495033", 
                "citation": "Schaafsma BE, Mieog JS, Hutteman M, van der Vorst JR, Kuppen PJ, L\u00f6wik CW, Frangioni JV, van de Velde CJ, Vahrmeijer AL. The clinical use of indocyanine green as a near-infrared fluorescent contrast agent for image-guided oncologic surgery. J Surg Oncol. 2011 Sep 1;104(3):323-32. doi: 10.1002/jso.21943. Epub 2011 Apr 14. Review."
            }, 
            {
                "PMID": "17670291", 
                "citation": "Takahashi M, Ishikawa T, Higashidani K, Katoh H. SPY: an innovative intra-operative imaging system to evaluate graft patency during off-pump coronary artery bypass grafting. Interact Cardiovasc Thorac Surg. 2004 Sep;3(3):479-83."
            }, 
            {
                "PMID": "11034240", 
                "citation": "Weber SM, Jarnagin WR, DeMatteo RP, Blumgart LH, Fong Y. Survival after resection of multiple hepatic colorectal metastases. Ann Surg Oncol. 2000 Oct;7(9):643-50."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01738217"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": {
            "PMID": "19435621", 
            "citation": "Slim K, Blay JY, Brouquet A, Chatelain D, Comy M, Delpero JR, Denet C, Elias D, Fl\u00e9jou JF, Fourquier P, Fuks D, Glehen O, Karoui M, Kohneh-Shahri N, Lesurtel M, Mariette C, Mauvais F, Nicolet J, Perniceni T, Piessen G, Regimbeau JM, Rouanet P, sauvanet A, Schmitt G, Vons C, Lasser P, Belghiti J, Berdah S, Champault G, Chiche L, Chipponi J, Chollet P, De Ba\u00e8re T, D\u00e9chelotte P, Garcier JM, Gayet B, Gouillat C, Kianmanesh R, Laurent C, Meyer C, Millat B, Msika S, Nordlinger B, Paraf F, Partensky C, Peschaud F, Pocard M, Sastre B, Scoazec JY, Scott\u00e9 M, Triboulet JP, Trillaud H, Valleur P. [Digestive oncology: surgical practices]. J Chir (Paris). 2009 May;146 Suppl 2:S11-80. Review. French."
        }, 
        "secondary_outcome": [
            {
                "measure": "First step: assess the ability to visualize the fluorescent anatomical areas", 
                "safety_issue": "No", 
                "time_frame": "During surgery on day 0"
            }, 
            {
                "description": "by using the images obtained during the surgery", 
                "measure": "First step: Quantify the fluorescence", 
                "safety_issue": "No", 
                "time_frame": "After the surgery, on day 0"
            }, 
            {
                "measure": "First step: assess the ability to review saved data", 
                "safety_issue": "No", 
                "time_frame": "After the surgery, on day 0"
            }, 
            {
                "description": "Assessment of the number of lesions detected thanks to the medical device. The malignant aspect must be confirmed by an anatomopathological analysis.", 
                "measure": "Second step: assess the ability to detect tumor lesions which were not previously known.", 
                "safety_issue": "No", 
                "time_frame": "During surgery on day 0"
            }, 
            {
                "description": "Number of patients for whom the surgery would be modified after using Fluobeam.", 
                "measure": "Second step: assess the rate of modifications of the surgical plan.", 
                "safety_issue": "No", 
                "time_frame": "During surgery on day 0"
            }, 
            {
                "description": "It will be measured using the residual fluorescence and the pathology analysis", 
                "measure": "Second step: assess the quality of the resection margins.", 
                "safety_issue": "No", 
                "time_frame": "After the surgery on day 0"
            }, 
            {
                "description": "It will be assessed after the anatomopathological analysis.", 
                "measure": "Second step: assess the depth limit of detection of the fluorescence.", 
                "safety_issue": "No", 
                "time_frame": "After the pathology analysis on day 0"
            }, 
            {
                "description": "From images obtained during the surgery and from the sample analysed by a pathologist.", 
                "measure": "Second step: Quantify the fluorescence.", 
                "safety_issue": "No", 
                "time_frame": "After the surgery, on day 0"
            }, 
            {
                "measure": "Second step: assess the number of asepsis due to Fluobeam", 
                "safety_issue": "No", 
                "time_frame": "During surgery on day 0"
            }, 
            {
                "description": "Assessment of the number of lesions detected thanks to the medical device. The malignant aspect must be confirmed by an anatomopathological analysis", 
                "measure": "Third step: assess the ability to detect tumor lesions which were not previously known.", 
                "safety_issue": "No", 
                "time_frame": "During surgery on day 0"
            }, 
            {
                "description": "From images obtained during the surgery and from the sample analysed by a pathologist.", 
                "measure": "Third step: quantify the fluorescence.", 
                "safety_issue": "No", 
                "time_frame": "After the surgery on day 0"
            }, 
            {
                "description": "one before and one during the surgery (tumor detection and segment targeting respectively).", 
                "measure": "Third step: assess the ability to administer two doses of ICG in the same patient", 
                "safety_issue": "No", 
                "time_frame": "On day 0"
            }, 
            {
                "measure": "Third step: assess the number of asepsis due to Fluobeam", 
                "safety_issue": "No", 
                "time_frame": "During surgery on day 0"
            }, 
            {
                "description": "Number of lesions seen on images before and during the surgery and detected by Fluobeam.", 
                "measure": "Third step: assess the ability of the medical device to detect tumor lesions which were previously known.", 
                "safety_issue": "No", 
                "time_frame": "On day 0"
            }
        ], 
        "source": "Centre Leon Berard", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centre Leon Berard", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}